Global RNAi Technology Market is Expected to Showcase Significant Growth at a CAGR of ~14% by 2034

Global RNAi Technology Market is Expected to Showcase Significant Growth at a CAGR of ~14% by 2034 | DelveInsight

The global RNAi technology market is witnessing strong growth, driven by the increasing approval and commercialization of RNAi-based therapeutics for rare genetic, metabolic, cardiovascular, and liver diseases. Advancements in RNA delivery technologies, including lipid nanoparticles (LNPs) and GalNAc conjugates, have significantly improved the safety and efficacy of RNAi drugs, accelerating clinical development. Rising investments in biotechnology research, expanding strategic collaborations between pharmaceutical and biotech companies, and growing applications of RNAi in precision medicine and oncology are further supporting market expansion.

DelveInsight's RNAi Technology Market Insights report provides the current and forecast market analysis, individual leading RNAi technology companies' market shares, challenges, RNAi technology market drivers, barriers, trends, and key RNAi technology companies in the market.

2025 RNAi Technology Market Size: USD 1.6 Billion

2034 Projected RNAi Technology Market Size: USD 5.5 Billion

RNAi Technology Market Growth Rate (2026-2034): ~14%

Largest RNAi Technology Market: North America

Largest Molecule Type Segment: siRNA Category

Key Companies in the RNAi Technology Market: Alnylam Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Novo Nordisk A/S through Dicerna, Silence Therapeutics plc, Novartis AG, Ionis Pharmaceuticals, Inc., Thermo Fisher Scientific Inc., Merck KGaA, Sirnaomics, Inc., Sanofi S.A., and others

To read more about the latest highlights related to the RNAi technology news, get a snapshot of the key highlights @ https://www.delveinsight.com/report-store/rnai-technology-market

Key Factors Contributing to the Rise in Growth of the RNAi Technology Market